Blueprint Medicines Corporation or Grifols, S.A.: Who Manages SG&A Costs Better?

SG&A Cost Management: Blueprint vs. Grifols

__timestampBlueprint Medicines CorporationGrifols, S.A.
Wednesday, January 1, 20147890000660772000
Thursday, January 1, 201514456000736435000
Friday, January 1, 201619218000775266000
Sunday, January 1, 201727986000860348000
Monday, January 1, 201847928000814775000
Tuesday, January 1, 201996388000942821000
Wednesday, January 1, 2020157743000985616000
Friday, January 1, 20211952930001061508000
Saturday, January 1, 20222373740001190423000
Sunday, January 1, 20232951410001254234000
Monday, January 1, 2024359272000
Loading chart...

Igniting the spark of knowledge

SG&A Cost Management: Blueprint Medicines vs. Grifols

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Blueprint Medicines Corporation and Grifols, S.A. have shown contrasting approaches. Blueprint Medicines, a biopharmaceutical company, has seen its SG&A expenses grow from approximately $7.9 million in 2014 to nearly $295 million in 2023, marking a staggering increase of over 3,600%. This reflects its aggressive expansion and investment in growth.

Conversely, Grifols, a global healthcare company, maintained a more stable SG&A trajectory, with expenses rising from about $661 million in 2014 to $1.25 billion in 2023, a more modest 89% increase. This stability suggests a focus on efficiency and cost control.

Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies, offering a window into their financial health and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025